Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years [0.03%]
依折麦布在保加利亚治疗杂合子家族性高胆固醇血症中的成本效益：通过有效治疗的患者年数来衡量健康获益
Borislav Borissov,Michael Urbich,Boryana Georgieva et al.
Borislav Borissov et al.
Background: An elevated level of low-density lipoprotein cholesterol (LDL-C) constitutes one of the most important modifiable risk factors for cardiovascular disease (CVD). Individuals with heterozygous familial hypercholesterolaemia (HeFH)...
Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy [0.03%]
伊布替尼治疗意大利淋巴滤泡性边缘带B细胞淋巴瘤患者的成本效益分析
Andrea Aiello,Anna D&#x;Ausilio,Roberta Lo Muto et al.
Andrea Aiello et al.
Background and Objective: Ibrutinib has recently been approved in Europe for Waldenström Macroglobulinemia (WM) in symptomatic patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for ch...
Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry [0.03%]
波兰药品和医疗器械报销制度改革及其对市场准入和制药行业的影响分析报告
Karolina Badora,Aleksandra Caban,Cécile Rémuzat et al.
Karolina Badora et al.
In Poland, two proposed amendments to the reimbursement act are currently in preparation; these are likely to substantially change the pricing and reimbursement landscape for both drugs and medical devices. Proposed changes include: alignme...
A Millier,M Horváth,F Ma et al.
A Millier et al.
Background: It is unclear if the burden associated with schizophrenia is affected by the type and severity of patient's symptoms. Objective: This study aims to quantify healthcare resource use associated with different profiles of schizophr...
A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting [0.03%]
精神分裂症中的耐受性负担指数：在临床试验不良事件报告中结合患者观点
Clément François,Alice Guiraud-Diawara,Christophe Lançon et al.
Clément François et al.
Background: Adverse event (AE) reporting in clinical trials does not fully capture the patient-level perspective and comparing tolerability across treatments or among studies is difficult. Objective: This study was designed to develop a tre...
Creating an index to measure health state of depressed patients in automated healthcare databases: the methodology [0.03%]
一种测量自动化医疗数据库中抑郁患者健康状况的指标体系：方法学研究
Clément François,Adrian Tanasescu,François-Xavier Lamy et al.
Clément François et al.
Background and objective: Automated healthcare databases (AHDB) are an important data source for real life drug and healthcare use. In the filed of depression, lack of detailed clinical data requires the use of binary proxies with important...
The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change [0.03%]
外部参考定价的反作用：欧洲12个国家的孤儿药可及性比较以及政策呼吁
K E Young,I Soussi,M Toumi
K E Young
Objective: The study compared the relative cost differences of similar orphan drugs among high and low GDP countries in Europe: Bulgaria, France, Germany, Greece, Hungary, Italy, Norway, Poland, Romania, Spain, Sweden, UK. Methods: Annual t...
Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016 [0.03%]
基于多准则决策分析的卫生保健决策支持——FIFARMA项目(2016年)
Julia I Drake,Juan Carlos Trujillo de Hart,Clara Monleón et al.
Julia I Drake et al.
Background and objectives: MCDA is a decision-making tool with increasing use in the healthcare sector, including HTA (Health Technology Assessment). By applying multiple criteria, including innovation, in a comprehensive, structured and ex...
Development of an instrument evaluating the impact of surgeon-patient relationship in patients on sick leave [0.03%]
评估外科医生-患者关系对病假患者影响的量表研制
Thierry Dubert,Cedric Girault,Alexandre Kilink et al.
Thierry Dubert et al.
Background: To date, no specific instruments exist to measure the quality of the patient-surgeon relationship despite its potential to influence clinical and economic outcomes in patients undergoing surgery for musculoskeletal disorders (MS...
Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test [0.03%]
按揭付款可增加英格兰NET预算影响测试下患者接受创新细胞和基因治疗的渠道
Jesper Jørgensen,Panos Kefalas
Jesper Jørgensen
Background: Cell and gene therapies have the potential to provide therapeutic breakthroughs, but the high costs of researching, developing, manufacturing and delivering them translate into prices that may challenge healthcare budgets. Vario...